Clinical Trial Search

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale

Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52

Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days

Primary: Main Reason for Testing for COVID-19 — 1632; 493; 238; 343 Participants

Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Completion of COVID-19 Test — 72; 60 Participants

Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020

Primary: Testing Barriers and Hesitancy — 0.29; 0.24 score on a scale — p=0.09

Primary: Instrumental Activities of Daily Living and Activities of Daily Living (I/ADL) Score — 3.40; 3.05; 3.50; 3.40 I/ADL Score — p=0.77

Primary: Viral Confirmation — 6; 0 Participants

Primary: COVID-19 Prevention Health Behaviors 1 — 6.0; 6.7; 4.8 score on a scale — p=.26

Primary: Number and Severity of Confirmed COVID-19 Infections Among Cancer Centre Staff and Patients at 12 Months — 55; 36 Participants

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements

Primary: Body Temperature — 98.1 degrees Fahrenheit

Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants

Primary: Stage 1: Completion of COVID-19 Test After First Randomization — 78; 71; 0; 0 participants

Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…

Primary: 30 Candidate Ag Test Self-collections — 53; 0 Participants

Primary: Positive Percent Agreement — 53; 2 Participants

Primary: Number of Samples Tested — 3692 samples

Primary: Number Infected With COVID-19 — 29; 141 Participants

Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers

Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77

Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants

Primary: Percentage of Clinical Agreement Between NOWDx COVID-19 Test and Emergency Use Authorized or FDA Cleared Comparator. — 91.5; 95.4 percentage of results matching PCR